Cooperative effect of Bifidobacteria lipoteichoic acid combined with 5-fluorouracil on hepatoma-22 cells growth and apoptosis

Bulletin du Cancer

Volumn 102, Issue 3, 2015, Pages 204-212

  Guo, Bin ^a   Xie, Ning ^a   Wang, Yue ^b  

^a AFFILIATED HOSPITAL OF NORTH SICHUAN MEDICAL COLLEGE   (China)

^b CHENGDU MEDICAL COLLEGE   (China)

Author keywords

5 fluorouracil; Apoptosis; Bifidobacterium; Immune function; Lipoteichoic acid

Indexed keywords

BETA ACTIN; CASPASE 3; CD4 ANTIGEN; FLUOROURACIL; INTERLEUKIN 2 RECEPTOR ALPHA; LIPOTEICHOIC ACID; MESSENGER RNA; PROTEIN BAX; PROTEIN BCL 2; TRANSCRIPTION FACTOR FOXP3; ANTINEOPLASTIC AGENT; FORKHEAD TRANSCRIPTION FACTOR; FOXP3 PROTEIN, MOUSE; HAVCR2 PROTEIN, MOUSE; LIPOPOLYSACCHARIDE; TEICHOIC ACID; TUMOR PROTEIN; VIRUS RECEPTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; BIFIDOBACTERIUM BIFIDUM; CANCER INHIBITION; CD25+ T LYMPHOCYTE; CD4+ T LYMPHOCYTE; CELL DEATH; CELL DENSITY; CELL GROWTH; CELL INFILTRATION; CELLULAR IMMUNITY; CONTROLLED STUDY; DOWN REGULATION; DRUG EFFICACY; FEMALE; GRANULOCYTE; HEPATOCELLULAR CARCINOMA CELL LINE; INFLAMMATORY CELL; LIVER CELL CARCINOMA; LYMPHOCYTIC INFILTRATION; MOUSE; NONHUMAN; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; REGULATORY T LYMPHOCYTE; SPLEEN CELL; T LYMPHOCYTE SUBPOPULATION; TUMOR GROWTH; TUMOR VOLUME; UPREGULATION; WESTERN BLOTTING; ANIMAL; BAGG ALBINO MOUSE; BIFIDOBACTERIUM; CANCER TRANSPLANTATION; CARCINOMA, HEPATOCELLULAR; CELL PROLIFERATION; CHEMICALLY INDUCED; CHEMISTRY; CYTOLOGY; DRUG EFFECTS; GENETICS; LIVER NEOPLASMS; METABOLISM; NECROSIS; PATHOLOGY; RANDOMIZATION; SPLEEN; T LYMPHOCYTE; TUMOR CELL LINE;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; BCL-2-ASSOCIATED X PROTEIN; BIFIDOBACTERIUM; CARCINOMA, HEPATOCELLULAR; CASPASE 3; CELL LINE, TUMOR; CELL PROLIFERATION; FEMALE; FLUOROURACIL; FORKHEAD TRANSCRIPTION FACTORS; IMMUNITY, CELLULAR; LIPOPOLYSACCHARIDES; LIVER NEOPLASMS; MICE; MICE, INBRED BALB C; NECROSIS; NEOPLASM PROTEINS; NEOPLASM TRANSPLANTATION; PROTO-ONCOGENE PROTEINS C-BCL-2; RANDOM ALLOCATION; RECEPTORS, VIRUS; RNA, MESSENGER; SPLEEN; T-LYMPHOCYTES; TEICHOIC ACIDS;

EID: 84927748793     PISSN: 00074551     EISSN: 17696917     Source Type: Journal    
DOI: 10.1016/j.bulcan.2014.09.003     Document Type: Article

References (25)

1. Lin DY, Lin SM, Liaw YF. Non-surgical treatment of hepatocellular carcinoma. J Gastroenterol Hepatol 1997;12(9-10):S319-28.
2. Quoix E, Ramlau R, Westeel V. Therapeutic vaccination with TG4010 and first-line chemotherapy in advanced non-small-cell lung cancer: a controlled phase 2B trial. Lancet Oncol 2011;12(12):1125-33.
3. Koido S, Homma S, Takahara A. Immunotherapy synergizes with chemotherapy targeting pancreatic cancer. Immunotherapy 2012;4(1):5-7.
4. Patt YZ, Hassan MM, Lozano RD. Phase II trial of systemic continuous fluorouracil and subcutaneous recombinant interferon Alfa-2b for treatment of hepatocellular carcinoma. J Clin Oncol 2003;21(3):421-7.
5. Sekine K, Ohta J, Onishi M. Analysis of antitumor properties of effector cells stimulated with a cell wall preparation (WPG) of Bifidobacterium infantis. Biol Pharm Bull 1995;18(1):148-53.
6. Sutcliffe IC, Hogg SD. Extraction of lipoteiehoic acid from Streptococcus mutans with the non-ionic detergent TritonX-114. J Microbiol Methods 1993;17(3):215-25.
7. Jing Wang, Zi-Rong Yang, Wei-Guo Dong. Cooperative inhibitory effect of sinomenine combined with 5-fluorouracil on esophageal carcinoma. World J Gastroenterol 2013;19(45):8292-300.
8. Malmberg KJ. Effective immunotherapy against cancer: a question of overcoming immune suppression and immune escape? Cancer Immunol Immunother 2004;53(10):879-92.
9. Martin A, Lillehoj HS, Kaspers B. Mitogen-induced lymphocyte proliferation and interferon production following coccidia infection. Avian Dis 1994;38(2):262-8.
10. Beyer M, Schultze JL. Regulatory T cells in cancer. Blood 2006;108(3):804-11.
11. Zou W. Regulatory T cells, tumor immunity and immunotherapy. Nat Rev Immunol 2006;6(4):295-307.
12. Yagi H, Nomura T, Nakamura K. Crucial role of FOXP3 in the development and function of human CD25+CD4+ regulatory T cells. Int Immunol 2004;16(11):1643-56.
13. Ormandy LA, Hillemann T, Wedemeyer H. Increased populations of regulatory T cells in peripheral blood of patients with hepatocellular carcinoma. Cancer Res 2005;65(6):2457-64.
14. Miller AM, Lundberg K, Ozenci V. CD4 +CD25high T cells are enriched in the tumor and peripheral blood of prostate cancer patients. J Immunol 2006;177(10):7398-405.
15. Han Y, Wu J, Bi L, Malignant B. Cells induce the conversion of CD4CD25 T cells to regulatory T cells in B-cell non-Hodgkin lymphoma. PLoS One 2011;6(12):e28649.
16. Perrone G, Ruffini PA, Catalano V. Intratumoural FOXP3-positive regulatory T cells are associated with adverse prognosis in radically resected gastric cancer. Eur J Cancer 2008;44(13):1875-82.
17. Duan Y, Xu RS, Wu HW. Effects of 89SrCl2 treatment on CD4+ CD25+ regulatory T cells and its Foxp3 mRNA expression in cancer patients with bone metastases. Sichuan Da Xue Xue Bao Yi Xue Ban 2011;42(5):649-52.
18. Yang ZZ, Novak AJ, Stenson MJ. Intratumoral CD4+CD25+ regulatory T cell-mediated suppression of infiltrating CD4+ T cells in B-cell non-Hodgkin lymphoma. Blood 2006;107(9):3639-46.
19. Casares N, Arribillaga L, Sarobe P. CD4 +/CD25+ regulatory cells inhibit activation of tumor-primed CD4+ T cells with IFN-gamma-dependent antiangiogenic activity, as well as long-lasting tumor immunity elicited by peptide vaccination. J Immunol 2003;171(11):5931-9.
20. Mariat C, Sanchez-Fueyo A, Alexopoulos SP. Regulation of T cell dependent immune responses by TIM family members. Philos Trans R Soc Lond B Biol Sci 2005;360(1461):1681-5.
21. Wang Y, Yang P, Li B. Expression of Tim-3 is transiently increased before development of anterior chamber-as-sociated immune deviation. Ocul Immunol Inflamm 2006;14(3):151-6.
22. Sanchez-Fueyo A, Tian J, Picarella D. Tim-3 inhibits T helper type 1 mediated auto-and alloimmune responses and promotes immunological tolerance. Nat Immunol 2003;4(11):1093-101.
23. Wang F, He W, Yuan J. Activation of Tim-3-Galectin-9 pathway improves survival of fully allogenic skin grafts. Transpl Immunol 2008;19(1):12-9.
24. Librenjak D, Situm M, Eterovic D. Immunoprophylactic intravesical application of bacillus Calmette-Guerin after transurethral resection of superficial bladder cancer. Croat Med J 2003;44(2):187-92.
25. Krieg AM. Immune effects and mechanisms of action of CpG motifs. Vaccine 2000;19(6):618-22.